Novartis Ag ADR (NVS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 06-2012 | 03-2012 | 12-2011 | 09-2011 | 06-2011 | |
| Cash Flows From Operating Activities | |||||
| Net Income | 4,944,000 | 2,269,000 | 9,072,000 | 8,035,000 | 5,547,000 |
| Depreciation Amortization | 2,338,000 | 1,144,000 | 5,980,000 | 4,016,000 | 2,588,000 |
| Income taxes - deferred | 850,000 | 390,000 | -2,435,000 | 1,477,000 | 1,057,000 |
| Accounts receivable | N/A | N/A | -732,000 | N/A | N/A |
| Accounts payable and accrued liabilities | N/A | N/A | 195,000 | N/A | N/A |
| Other Working Capital | -3,140,000 | -1,992,000 | 1,370,000 | -3,640,000 | -3,412,000 |
| Other Operating Activity | 509,000 | 705,000 | 859,000 | -301,000 | -427,000 |
| Operating Cash Flow | $5,501,000 | $2,516,000 | $14,309,000 | $9,587,000 | $5,353,000 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | 9,000 | 15,000 | 1,595,000 | 1,594,000 | 1,604,000 |
| PPE Investments | -812,000 | -248,000 | -2,106,000 | -661,000 | -176,000 |
| Net Acquisitions | -43,000 | N/A | -569,000 | -569,000 | -569,000 |
| Purchase Of Investment | N/A | N/A | -151,000 | N/A | N/A |
| Sale Of Investment | N/A | N/A | 59,000 | N/A | N/A |
| Purchase Sale Intangibles | -322,000 | -212,000 | 423,000 | -332,000 | -258,000 |
| Other Investing Activity | -322,000 | -212,000 | 380,000 | -332,000 | -258,000 |
| Investing Cash Flow | $-1,168,000 | $-445,000 | $-792,000 | $32,000 | $601,000 |
| Cash Flows From Financing Activities | |||||
| Change In Short Term Borrowing | 2,704,000 | 4,183,000 | -3,054,000 | 648,000 | 3,672,000 |
| Debt Issued | N/A | N/A | 281,000 | N/A | N/A |
| Debt Repayment | N/A | N/A | -28,000 | N/A | N/A |
| Common Stock Issued | N/A | 211,000 | 163,000 | N/A | N/A |
| Common Stock Repurchased | -61,000 | N/A | -6,815,000 | -5,964,000 | -5,312,000 |
| Dividend Paid | -6,030,000 | -6,010,000 | -5,571,000 | -5,368,000 | -5,368,000 |
| Other Financing Activity | -27,000 | -126,000 | 0 | -120,000 | -36,000 |
| Financing Cash Flow | $-3,414,000 | $-1,742,000 | $-15,024,000 | $-10,804,000 | $-7,044,000 |
| Exchange Rate Effect | -30,000 | 3,000 | -103,000 | -48,000 | 2,000 |
| Beginning Cash Position | 3,709,000 | 3,709,000 | 5,319,000 | 5,319,000 | 5,319,000 |
| End Cash Position | 4,598,000 | 4,041,000 | 3,709,000 | 4,086,000 | 4,231,000 |
| Net Cash Flow | $889,000 | $332,000 | $-1,610,000 | $-1,233,000 | $-1,088,000 |
| Free Cash Flow | |||||
| Operating Cash Flow | 5,501,000 | 2,516,000 | 14,309,000 | 9,587,000 | 5,353,000 |
| Capital Expenditure | -1,016,000 | -412,000 | -2,167,000 | -1,382,000 | -872,000 |
| Free Cash Flow | 4,485,000 | 2,104,000 | 12,142,000 | 8,205,000 | 4,481,000 |